PRCT Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Procept Biorobotics Corp (PRCT) is not a strong buy at this moment for a beginner investor with a long-term strategy. The stock faces significant headwinds, including bearish technical indicators, disappointing financial performance, and mixed analyst sentiment. While there are some positive aspects, such as insider buying and potential long-term growth opportunities, the lack of immediate catalysts and the company's current challenges make it prudent to hold off on investing right now.
The technical indicators are mixed to bearish. The MACD is positive and expanding, but RSI is neutral at 50.722, showing no clear signal. Moving averages are bearish (SMA_200 > SMA_20 > SMA_5), indicating a downward trend. The stock is trading near its pivot level of 24.306, with resistance at 25.54 and support at 23.072.
Insiders are buying, with a 1235.17% increase in buying activity over the last month. The company has laid out a case for sustainable 25% growth through 2027, which could be a long-term positive.
Hedge funds are selling, with a 465.92% increase in selling activity over the last quarter. Analysts have downgraded the stock, citing disappointing Q4 results, reduced guidance, and strategic challenges. The gross margin has dropped by 5.27% YoY, and the company is not generating profits, with a net income of -$29.85M in Q4 2025.
In Q4 2025, revenue increased by 11.94% YoY to $76.38M, but net income remains negative at -$29.85M, albeit improving by 58.28% YoY. EPS improved to -0.53, up 51.43% YoY. However, gross margin dropped to 60.63%, down 5.27% YoY, indicating cost pressures.
Analysts have mixed to negative views. Recent downgrades and reduced price targets dominate the sentiment. The current average price target is around $30, with some analysts expressing concerns about the company's ability to meet growth expectations and overcome strategic challenges.
